| A phase II study of recombinant human alpha-interferon in advanced hormone-refractory prostate cancer. | |
| | |
MedLine Citation:
|
PMID: 1382829 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
To determine the efficacy of recombinant human leukocyte alpha-interferon (IFL-RA) in advanced hormone-refractory prostate cancer, the authors treated 40 patients with IFL-RA administered intramuscularly at a dose of 10 x 10(6) U/m2 three times weekly. Toxicity was substantial and necessitated at least a 50% dose reduction in all but five patients during the first 1-2 months of therapy. No responses were observed in patients with bone metastases, but complete and partial regression of nodal disease were observed in two patients with extraosseous disease (overall response rate, 5%; 95% confidence interval, 0.64-17.75%). The authors conclude that IFL-RA cannot be recommended at this dose and schedule in patients with advanced prostate cancer, but additional study of its use in patients with nodal disease may be warranted. |
| | |
Authors:
|
C M van Haelst-Pisani; R L Richardson; J Su; J C Buckner; R G Hahn; S Frytak; L K Kvols; P A Burch |
Related Documents
:
|
21790859 - Association between the expression pattern of p16, prb and p53 and the response to intr... 18494829 - Vascular-targeted photodynamic therapy (padoporfin, wst09) for recurrent prostate cance... 21879269 - Is the 1-cm rule of distal bowel resection margin in rectal cancer based on clinical ev... 7617839 - Carcinoma of the prostate: a model for management under impending health care system re... 12441949 - Longitudinal comparison of sexual function after 3-dimensional conformal radiation ther... 1422689 - Treatment of advanced localised prostatic cancer by orchiectomy, radiotherapy, or combi... 9258089 - Late urological complications and malignancies after curative radiotherapy for gynecolo... 12667419 - Chemotherapeutic advances in pancreatic cancer. 22531769 - Predicting the risk of lymph node invasion during radical prostatectomy using the europ... |
Publication Detail:
|
Type: Clinical Trial; Clinical Trial, Phase II; Journal Article |
Journal Detail:
|
Title: Cancer Volume: 70 ISSN: 0008-543X ISO Abbreviation: Cancer Publication Date: 1992 Nov |
Date Detail:
|
Created Date: 1992-11-13 Completed Date: 1992-11-13 Revised Date: 2004-11-17 |
Medline Journal Info:
|
Nlm Unique ID: 0374236 Medline TA: Cancer Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 2310-2 Citation Subset: AIM; IM |
Affiliation:
|
Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adenocarcinoma
/
drug therapy,
secondary,
surgery,
therapy* Aged Clinical Protocols Humans Interferon-alpha / administration & dosage, adverse effects, therapeutic use* Leuprolide / therapeutic use Lymphatic Metastasis Male Middle Aged Orchiectomy Prostate-Specific Antigen / analysis Prostatic Neoplasms / drug therapy, surgery, therapy* Recombinant Proteins Remission Induction |
| Chemical | |
Reg. No./Substance:
|
0/Interferon-alpha; 0/Recombinant Proteins; 53714-56-0/Leuprolide; EC 3.4.21.77/Prostate-Specific Antigen |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D...
Next Document: Multiple cancers in the prostate. Morphologic features of clinically recognized versus incidental tu...